Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Active not recruiting 3

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Colorectal Neoplasms 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × OTHER × ALX148 × Clear all
NCT05787639 2026-05-19

Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)

University of California, San Diego

Phase 2 Active not recruiting
29 enrolled
Head & Neck

Oropharyngeal Neoplasms

NCT05467670 2026-03-04

Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer

University of Pittsburgh

Phase 2 Active not recruiting
16 enrolled
Gynecologic

Ovarian Neoplasms

NCT05167409 2025-01-13

A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer

University of Colorado, Denver

Phase 2 Active not recruiting
48 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡